Billions of dollars will be earned by companies who can develop tests that improve the diagnosis of viral, bacterial, fungal and other disease threats. The only question is which companies? Will it be the existing leaders in the field, like Abbott, Roche and biomerieux? or will new competitors emerge.
The history of IVD would seem to point to an answer. New companies, able to innovate faster, will share in the revenue.
What is that revenue? Last week, Eye On IVD’s webinar detailed the market for infectious diseases with an eye to 2035. Of all IVD market categories, the webinar stated, infectious disease testing offers the most growth, stability and entry points. According to the presentation, there is a 23.1 billion-dollars in NEW revenues to be earned between 2024 and 2035 marketing in vitro diagnostic products that detect infectious disease.
The webinar further detailed leading companies in the market, top growth areas, and revealed friction points where there is a market but customers are looking for improvement in current diagnostics. These include respiratory diseases, sepsis and emerging infections.
Subscribe to Eye On IVD for continued updates on this market.
